OliX Pharmaceuticals Expands Ocular Disease Pipeline; Adds OLX304A for the Treatment of Retinitis Pigmentosa

SUWON,South Korea,May 10,2019 -- OliX Pharmaceuticals,Inc. (KOSDAQ: 226950),a leading developer of RNAi therapeutics,announced todayan expansion of its ocular disease pipeline. Specifically,the company announced that OLX304A has been added to develop an RNAi therapeutic with a novel target (undisclosed) for treatment of Retinitis Pigmentosa (RP) in a presentation at the Investor Relations Meeting in Seoul on May 10th.

"We have confirmed the strong potential of treating RP using our cp-asiRNA platform technology which is an optimal siRNA technology for developing ocular therapeutics. We look forward to advancing OLX304A as a highly innovative approach to benefit RP patients," said Dong-ki Lee,Ph.D.,the founder and CEO of OliX.

OLX304A is a program to develop a treatment that targets a single gene for RP patients regardless of their disease-causing gene mutation. This strategy is different from the conventional treatment development strategies for RP which target individual disease-causing genes.

An IND application of OLX304A program is planned to be submitted to the US FDA to initiate a Phase 1 within the first half of next year.

OliX Pharmaceuticals,Inc.

OliX is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes,based on its own proprietary RNAi technology. The company is currently developing novel therapeutic programs for treatment of various diseases with high unmet medical needs,including hypertrophic scar,dry & wet age-related macular degeneration (AMD),subretinal fibrosis,Retinitis Pigmentosa and idiopathic pulmonary fibrosis (IPF).

Learn more: http://www.olixpharma.com/main/main.php

View original content to download multimedia:/news-releases/olix-pharmaceuticals-expands-ocular-disease-pipeline-adds-olx304a-for-the-treatment-of-retinitis-pigmentosa-300847844.html

Contact:

OliX Pharmaceuticlas,Inc.

JOHN YOHAN LEE,Investor and Media

yohani@olixpharma.com